FDA label c857d923-58dd-56fc-e600-80c809ebd6c7

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
147ac314-1b2a-4c17-8c51-57cfe361b7fb
SPL ID
c857d923-58dd-56fc-e600-80c809ebd6c7
Version
6
Effective date
2011-12-22
Source export date
2026-09-28
Source partition
2
Source file
https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-09-28/f7d2b6e3f8600cd856280ab55a9c6fa54a642647191d164f9d1110e89f3f4097/drug-label-0002-of-0014.json.zip
Source manifest SHA-256
cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run
20260929T050834Z
Imported at
2026-09-29 05:16:41

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

ADVERSE REACTIONS The table below shows the frequencies of the adverse events that occurred in >5% of the subjects in three placebo-controlled North American studies, in which patients in the active treatment arm received 30 mg, 60 mg, 120 mg or 240 mg of ISMN as Isosorbide mononitrate extended-release tablets once daily. In parentheses, the same table shows the frequencies with which these adverse events were associated with the discontinuation of treatment. Overall, 8% of the patients who received 30 mg, 60 mg, 120 mg or 240 mg of ISMN in the three placebo-controlled North American studies discontinued treatment because of adverse events. Most of these discontinued because of headache. Dizziness was rarely associated with withdrawal from these studies. Since headache appears to be a dose-related adverse effect and tends to disappear with continued treatment, it is recommended that Isosorbide mononitrate extended-release tablets treatment be initiated at low doses for several days before being increased to desired levels. FREQUENCY AND ADVERSE EVENTS (DISCONTINUED)* Three Controlled North American Studies Dose Placebo 30 mg 60 mg 120 mg** 240 mg** * Some individuals discontinued for multiple reasons ** Patients were started on 60 mg and titrated to their final dose. Patients 96 60 102 65 65 Headache 15% (0%) 38% (5%) 51% (8%) 42% (5%) 57% (8%) Dizziness 4% (0%) 8% (0%) 11% (1%) 9% (2%) 9% (2%) In addition, the three North American trials were pooled with 11 controlled trials conducted in Europe. Among the 14 controlled trials, a total of 711 patients were randomized to Isosorbide mononitrate extended-release tablets. When the pooled data were reviewed, headache and dizziness were the only adverse events that were reported by >5% of patients. Other adverse events, each reported by ≤5% of exposed patients, and in many cases of uncertain relation to drug treatment, were: Autonomic Nervous System Disorders : Dry mouth, hot flushes. Body as a Whole: Asthenia, back pain, chest pain, edema, fatigue, fever, flu-like symptoms, malaise, rigors. Cardiovascular Disorders, General: Cardiac failure, hypertension, hypotension. Central and Peripheral Nervous System Disorders: Dizziness, headache, hypoesthesia, migraine, neuritis, paresis, paresthesia, ptosis, tremor, vertigo. Gastrointestinal System Disorders : Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gastric ulcer, gastritis, glossitis, hemorrhagic gastric ulcer, hemorrhoids, loose stools, melena, nausea, vomiting. Hearing and Vestibular Disorders : Earache, tinnitus, tympanic membrane perforation. Heart Rate and Rhythm Disorders: Arrhythmia, arrhythmia atrial, atrial fibrillation, bradycardia, bundle branch block, extrasystole, palpitation, tachycardia, ventricular tachycardia. Liver and Biliary System Disorders : SGOT increase, SGPT increase. Metabolic and Nutritional Disorders : Hyperuricemia, hypokalemia. Musculoskeletal System Disorders: Arthralgia, frozen shoulder, muscle weakness, musculoskeletal pain, myalgia, myositis,tendon disorder, torticollis. Myo-, Endo-, Pericardial and Valve Disorders : Angina pectoris aggravated, heart murmur, heart sound abnormal, myocardial infarction, Q-Wave abnormality. Platelet, Bleeding and Clotting Disorders : Purpura, thrombocytopenia. Psychiatric Disorders : Anxiety, concentration impaired, confusion, decreased libido, depression, impotence, insomnia, nervousness, paroniria, somnolence. Red Blood Cell Disorder : Hypochromic anemia. Reproductive Disorders, Female: Atrophic vaginitis, breast pain. Resistance Mechanism Disorders: Bacterial infection,moniliasis, viral infection. Respiratory System Disorders: Bronchitis, bronchospasm, coughing, dyspnea, increased sputum, nasal congestion, pharyngitis, pneumonia, pulmonary infiltration, rales, rhinitis, sinusitis. Skin and Appendages Disorders : Acne, hair texture abnormal, increased sweating, pruritus, rash, skin nodule. Urinary System Disorders : Polyuria, renal calculus, urinary tract infection. Vascular (Extracardiac) Disorders : Flushing, intermittent claudication, leg ulcer, varicose vein. Vision Disorders : Conjunctivitis, photophobia, vision abnormal. In addition, the following spontaneous adverse event has been reported during the marketing of Isosorbide Mononitrate (ISMN): syncope.

adverse reactions table

<table frame="void" width="638"> <caption> FREQUENCY AND ADVERSE EVENTS (DISCONTINUED)*</caption> <thead> <tr> <td align="left" colspan="6" styleCode="BotruleLruleRruleToprule" valign="top"> Three Controlled North American Studies</td> </tr> <tr> <td align="left" styleCode="BotruleLruleRruleToprule" valign="top"> Dose</td> <td align="left" styleCode="BotruleLruleRruleToprule" valign="top"> Placebo</td> <td align="left" styleCode="BotruleLruleRruleToprule" valign="top"> 30 mg</td> <td align="left" styleCode="BotruleLruleRruleToprule" valign="top"> 60 mg</td> <td align="left" styleCode="BotruleLruleRruleToprule" valign="top"> 120 mg**</td> <td align="left" styleCode="BotruleLruleRruleToprule" valign="top"> 240 mg**</td> </tr> </thead> <tfoot> <tr> <td align="left" colspan="6" styleCode="BotruleLruleRruleToprule" valign="top"> * Some individuals discontinued for multiple reasons </td> </tr> <tr> <td align="left" colspan="6" styleCode="BotruleLruleRruleToprule" valign="top"> ** Patients were started on 60 mg and titrated to their final dose. </td> </tr> </tfoot> <tbody> <tr> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">Patients</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">96</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">60</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">102</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">65</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">65</td> </tr> <tr> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">Headache</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">15% (0%)</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">38% (5%)</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">51% (8%)</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">42% (5%)</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">57% (8%)</td> </tr> <tr> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">Dizziness</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">4% (0%)</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">8% (0%)</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">11% (1%)</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">9% (2%)</td> <td align="center" styleCode="BotruleLruleRruleToprule" valign="top">9% (2%)</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.